ntroduction: Central Nervous Tumors constitute 3% of cancer cases worldwide. The
incidence of CNS tumors in India ranges from 5-10 per 100,000 population, ranking 14th among
all other tumors and accounting for 2% of malignancies. The five most frequent tumors were
astrocytoma (47.3%), Medulloblastoma (11.4%), craniopharyngioma (9.7%), ependymal tumors
(4.8%), and nerve sheath tumors (4.1%). The tumor spectrum varies among different ages and
sexes. Materials and Methods: All the patients of CNS tumours who attended the Department of
Radiation Oncology, SAMC, and PGI from October 2010 to December 2019 are included in the
study. The medical records of 238 patients were evaluated, out of which only 102 were fit for
the study as per the inclusion and exclusion criteria. 

Results: The 3-year median overall survival (OS) of 8 years and Progression Free Survival
(PFS) of 7 years, while the 5-year median OS of 9 years and PFS of 7 years is recorded.
Glioblastoma (GBM) is the most aggressive out of all histologies, with a 2-year survival of
31% and a median OS of 8 months, as per our study. We got some good results with brainstem
glioma as well, with a 2-year survival of 40% and a median OS of 18 months.
Conclusion: The survival in CNS tumours has improved widely with adjuvant concurrent
chemoradiation postoperatively, and the better the resection is done, the better the survival is
seen.